Nitric oxide and cytokine-mediated inflammatory signaling pathway (NO/Cytokine Pathway)

The nitric oxide and cytokine-mediated inflammatory signaling pathway is a critical regulatory network involved in the coordination of the innate and adaptive immune responses (PubMed: PMC2854634). It involves the production of pro-inflammatory cytokines like TNF-alpha, IL-1, and IL-6, which bind to their respective receptors to activate downstream transcription factors such as NF-kappaB. These transcription factors induce the expression of the inducible nitric oxide synthase (iNOS) enzyme, leading to a significant increase in nitric oxide (NO) production (UniProt: P35228). While NO is essential for killing pathogens and regulating vascular tone, its chronic overproduction contributes to tissue damage and the pathogenesis of inflammatory disorders like rheumatoid arthritis and sepsis (StatPearls: NBK507821). Pharmacological intervention typically targets specific nodes within the pathway, such as cytokine neutralization or kinase inhibition, to dampen the inflammatory cascade. Understanding the crosstalk between NO and cytokine signaling is vital for developing therapies that reduce inflammation without compromising essential immune functions.

Other names

Inflammatory signaling pathwayCytokine-inducible nitric oxide synthase pathwayPro-inflammatory signaling cascade

Modulation of the pathway occurs through the inhibition of pro-inflammatory cytokines (e.g., TNF-alpha, IL-6), the inhibition of signaling kinases (e.g., JAK), or the direct inhibition of nitric oxide synthase (NOS) enzymes to reduce oxidative stress and inflammatory damage (PubMed: PMC4712936; StatPearls: NBK507821).